share_log

InMed Provides Update on INM-089 in the Treatment of Dry Age-Related Macular Degeneration

InMed Provides Update on INM-089 in the Treatment of Dry Age-Related Macular Degeneration

InMed 提供 INM-089 治療乾性年齡相關性黃斑變性的最新情況
InMed Pharmaceuticals ·  04/16 12:00
  • Small molecule drug acting as a preferential signaling ligand for CB1/CB2
  • Delivers improved retinal pigment epithelium integrity, neuroprotection and photoreceptor improvement in in vivo preclinical disease model
  • 小分子藥物用作 CB1/CB2 的優先信號配體
  • 改善視網膜色素上皮完整性、神經保護和光感受器改善 在活體中 臨床前疾病模型

Vancouver, British Columbia–(Newsfile Corp. – April 16, 2024) – InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a leader in the research, development, manufacturing, and commercialization of rare cannabinoids and proprietary cannabinoid analogs, today announced additional preclinical data for INM-089 further demonstrating positive pharmacological effects targeting dry Age-Related Macular Degeneration ("AMD").

不列顛哥倫比亞省溫哥華——(新聞檔案公司,2024年4月16日)——稀有大麻素和專有大麻素類似物研究、開發、製造和商業化的領導者InMed製藥公司(納斯達克股票代碼:INM)(“InMed” 或 “公司”)今天公佈了更多的 INM-089 臨床前數據,進一步顯示了針對乾性年齡相關性黃斑變性(“AMD”)的積極藥理作用。

Dr. Eric Hsu, SVP of Preclinical Research and Development, stated, "We are very excited with the data from recent preclinical studies demonstrating both significant functional and pathological improvements from INM-089 in the AMD model. While a few treatment options are currently available, their efficacy is limited and may be associated with several undesirable side effects. We see an opportunity for INM-089 to slow the progression and to fill a significant gap in the treatment of this chronic disease."

臨床前研究與開發高級副總裁 Eric Hsu 博士表示:“我們對最近的臨床前研究數據感到非常興奮,這些數據表明 INM-089 在 AMD 模型中進行了顯著的功能和病理改善。儘管目前有一些治療方案可供選擇,但其療效有限,可能與幾種不良副作用有關。我們認爲,INM-089 有機會減緩進展並填補這種慢性病治療的重大空白。”

Recent Preclinical Data

最近的臨床前數據

Data from a recent proof of concept study indicates that INM-089 may be more effective as a therapeutic treatment for dry AMD compared to neovascular, or wet, AMD. More specifically, data suggests INM-089 may be an important candidate for geographic atrophy ("GA") which is common in more advanced cases of dry AMD, affecting the center of the macula.

最近一項概念驗證研究的數據表明,與新生血管性或溼性 AMD 相比,INM-089 作爲乾性 AMD 的治療可能更有效。更具體地說,數據表明,INM-089 可能是地理萎縮(“GA”)的重要候選者,這種萎縮在更晚期的乾性 AMD 病例中很常見,會影響黃斑中心。

In vivo preclinical studies in AMD disease models demonstrated the following significant outcomes for INM-089:

在體內 AMD 疾病模型的臨床前研究表明,INM-089 具有以下顯著結果:

  • neuroprotection of photoreceptors as well as improved photoreceptors function;
  • improved integrity of retinal pigment epithelium; and
  • reduction in extracellular autofluorescent deposits, a hallmark of dry AMD.
  • 光感受器的神經保護以及感光器功能的改善;
  • 改善視網膜色素上皮的完整性;以及
  • 減少細胞外自熒光沉積,這是乾性 AMD 的標誌。

Previously, it was demonstrated that INM-089 preserved retinal function and improved the thickness of the outer nuclear layer of the retina, where photoreceptors are located, in an in vivo AMD disease model.

此前,已證明 INM-089 保留了視網膜功能並改善了視網膜外核層(感光器所在的位置)的厚度 在活體中 AMD 疾病模型。

Importance of CB1/CB2 Receptors

CB1/CB2 受體的重要性

INM-089 is proprietary small molecule compound acting as a preferential signaling ligand of cannabinoid receptor 1 ("CB1") and cannabinoid receptor 2 ("CB2"). CB1 and CB2 receptors are both part of the endocannabinoid system that is found throughout the human body and is responsible for many homeostatic functions. CB1 receptors are primarily located in the brain and central nervous system, while CB2 receptors are involved in modulating neuroinflammation and immune responses.

INM-089 是專有的小分子化合物,可作爲大麻素受體 1(“CB1”)和大麻素受體 2(“CB2”)的優先信號配體。CB1 和 CB2 受體都是內源性大麻素系統的一部分,內源性大麻素系統存在於人體各處,負責許多穩態功能。CB1 受體主要位於大腦和中樞神經系統中,而 CB2 受體則參與調節神經炎症和免疫反應。

Dry AMD – Unmet Medical Need

幹型 AMD — 未滿足的醫療需求

AMD is a 'back of the eye' disease in which a small area in the central portion of the retina, known as the macula, is damaged. AMD affects the central vision and the ability to see fine details. People with advanced AMD in both eyes cannot recognize faces, read, nor drive. Dry AMD is the most common form, accounting for 85-90% of all AMD cases and is a leading cause of blindness in the developed world. Dry AMD is caused by waste proteins and lipids (oily material) that begin to accumulate due to poor circulation and poor waste-flushing in the eye. The advanced stage of dry AMD is referred to as Geographic Atrophy, with approximately 5 million patients globally suffering from GA. The prevalence of GA is projected to continue to rise in the coming years, with an estimated 18.5 million cases globally by the year 2040.(1)

AMD 是一種 “眼後” 疾病,其中視網膜中央部分的一小部分區域(稱爲黃斑)受到損傷。AMD 會影響中心視覺和查看精細細節的能力。雙眼都裝有高級 AMD 的人無法識別人臉、讀取或開車。乾性 AMD 是最常見的形式,佔所有 AMD 病例的 85-90%,是發達國家的主要失明原因。乾性 AMD 是由廢蛋白和脂質(油性物質)引起的,這些廢物由於血液循環不良和眼睛的廢物沖洗不良而開始積累。乾性 AMD 的晚期被稱爲地理萎縮,全球約有 500 萬患者患有 GA。預計未來幾年胃腸炎的流行率將繼續上升,到2040年,全球估計有1,850萬例病例。(1)

Next Steps- Advancing Development Activities

下一步——推進開發活動

InMed has engaged a Contract Development and Manufacturing Organization ("CDMO") to assist in scale-up manufacturing process development of the active pharmaceutical ingredient ("API"). Furthermore, development work on drug product formulation continues internally to support the next stages of development activities.

InMed聘請了合同開發和製造組織(“CDMO”)來協助擴大活性藥物成分(“API”)的製造工藝開發。此外,內部繼續開展藥品配方開發工作,以支持下一階段的開發活動。

Additional preclinical activities are on-going to further understand the mechanism of action including receptor interactions and drug metabolism and pharmacokinetics ("DMPK") studies.

其他臨床前活動正在進行中,以進一步了解作用機制,包括受體相互作用以及藥物代謝和藥代動力學(“DMPK”)研究。

References:

參考文獻:

About InMed:

關於 inMed:

InMed Pharmaceuticals is a global leader in the manufacturing, development and commercialization of rare cannabinoids and proprietary cannabinoid analogs. We are a clinical-stage company developing a pipeline of proprietary cannabinoid-analog therapeutics and dedicated to delivering new treatment alternatives to patients that may benefit from cannabinoid-based pharmaceutical drugs. For more information, visit www.inmedpharma.com.

InMed Pharmicals是稀有大麻素和專有大麻素類似物的製造、開發和商業化的全球領導者。我們是一家處於臨床階段的公司,正在開發專有的大麻素類似物療法產品線,致力於爲可能受益於大麻素類藥物的患者提供新的治療替代方案。欲了解更多信息,請訪問 www.inmedpharma.com

Investor Contact:
Colin Clancy
Vice President, Investor Relations
and Corporate Communications
T: +1 604 416 0999
E: [email protected]

投資者聯繫人:
科林·克蘭西
投資者關係副總裁
和企業傳播
電話:+1 604 416 0999
E: [電子郵件保護]

Cautionary Note Regarding Forward-Looking Information:

關於前瞻性信息的警示說明:

This news release contains "forward-looking information" and "forward-looking statements" (collectively, "forward-looking information") within the meaning of applicable securities laws. Forward-Looking statements are frequently, but not always, identified by words such as "expects", "anticipates", "believes", "intends", "potential", "possible", "would" and similar expressions. Such statements, based as they are on current expectations of management, inherently involve numerous risks, uncertainties and assumptions, known and unknown, many of which are beyond our control. Forward-Looking information is based on management's current expectations and beliefs and is subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Without limiting the foregoing, forward-looking information in this news release includes, but is not limited to, statements about: the efficacy of INM-089, INM-089's ability to treat AMD, marketability and uses for INM-089, the results of further studies into INM-089 and the further development of InMed's AMD program.

本新聞稿包含適用證券法所指的 “前瞻性信息” 和 “前瞻性陳述”(統稱爲 “前瞻性信息”)。前瞻性陳述通常以 “期望”、“預期”、“相信”、“打算”、“潛力”、“可能”、“將” 等詞語和類似表述來識別,但並非總是如此。此類陳述基於管理層當前的預期,本質上涉及許多已知和未知的風險、不確定性和假設,其中許多是我們無法控制的。前瞻性信息基於管理層當前的預期和信念,存在許多風險和不確定性,這些風險和不確定性可能導致實際業績與前瞻性陳述中描述的結果存在重大差異。在不限制上述內容的前提下,本新聞稿中的前瞻性信息包括但不限於以下方面的陳述:INM-089 的功效、INM-089 治療AMD的能力、INM-089 的適銷性和用途、對INM-089 的進一步研究結果以及InMed的AMD計劃的進一步發展。

Additionally, there are known and unknown risk factors which could cause InMed's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information contained herein. A complete discussion of the risks and uncertainties facing InMed's stand-alone business is disclosed in InMed's Annual Report on Form 10-K and other filings with the Securities and Exchange Commission on www.sec.gov.

此外,還有一些已知和未知的風險因素可能導致InMed的實際業績、業績或成就與本文包含的前瞻性信息所表達或暗示的任何未來業績、業績或成就存在重大差異。InMed的10-K表年度報告以及向美國證券交易委員會提交的其他文件中披露了對InMed獨立業務面臨的風險和不確定性的完整討論 www.sec.gov

All forward-looking information herein is qualified in its entirety by this cautionary statement, and InMed disclaims any obligation to revise or update any such forward-looking information or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results, events or developments, except as required by law.

此處的所有前瞻性信息均受本警示聲明的全面限制,除非法律要求,否則InMed不承擔任何修改或更新任何此類前瞻性信息或公開宣佈爲反映未來業績、事件或發展而對本文包含的任何前瞻性信息進行任何修訂的結果的義務。

Corporate Logo

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/205639

要查看本新聞稿的源版本,請訪問 https://www.newsfilecorp.com/release/205639

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論